Kezar Life Sciences halts mid-stage trial for lupus treatment (updated)

Kezar Life Sciences

30/09/2024 14:04

(Adds details on study in paragraphs 2-4)
       Sept 30 (Reuters) - Kezar Life Sciences  KZR.O  said on
Monday it has stopped enrollment of new patients and dosing of
existing patients in its mid-stage study for treating a symptom
of lupus, following an independent committee's recommendation
after four deaths.
    Four fatal serious adverse events occurred during the course
of the trial in patients enrolled in the Philippines and
Argentina, according to Kezar.
    Review of the safety data from the trial by the committee
revealed three of the fatalities showed a common pattern of
symptoms and proximity to dosing, the company said.
    Kezar was testing the treatment, zetomipzomib, in patients
with active lupus nephritis, a type of kidney disease caused by
lupus.

 (Reporting by Sneha S K in Bengaluru; Editing by Shounak
Dasgupta)
 ((Sneha.SK@thomsonreuters.com))